{
    "clinical_study": {
        "@rank": "60655", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in\n      locally advanced or metastatic renal cell cancer and to evaluate the safety profile of\n      CP-461 in this patient population."
        }, 
        "brief_title": "Study of CP-461 in Patients With Advanced Renal Cell Cancer", 
        "completion_date": {
            "#text": "July 2003", 
            "@type": "Actual"
        }, 
        "condition": "Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Measurable metastatic or locally advanced disease.\n\n          2. Histologically confirmed renal cell cancer.\n\n          3. No radiotherapy within 4 weeks prior to entering the study.  No more than 1 prior\n             systemic therapy for advanced disease.  Prior adjuvant systemic therapy is allowed.\n             Patients must have fully recovered from the acute effects of prior therapy.\n\n          4. Expected remaining life span > or = three months.\n\n          5. ECOG performance status 0-2.\n\n          6. > or = 18 years of legal age.\n\n          7. Male patients, or non-pregnant and non-lactating female patients who are either using\n             adequate birth control, surgically sterile or post-menopausal.\n\n          8. Negative serum pregnancy test, if fertile female.\n\n          9. Willingness and ability to sign an informed consent document.\n\n        Exclusion Criteria:\n\n          1. Uncontrolled or symptomatic brain metastases.\n\n          2. Use of an investigational medication or device within one month of initiating study\n             therapy.\n\n          3. Absolute granulocyte count < or = 1500/mm3; Platelet count < or = 100,000/mm3; total\n             serum bilirubin above the upper limit of normal; serum creatinine > or = 2.2 mg/dL;\n             AST/ALT > 2.5 ULN.\n\n          4. Any condition or any medication which may interfere with the conduct of the study.\n\n          5. Current active malignancy other than renal cell cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "14", 
        "firstreceived_date": "May 7, 2002", 
        "id_info": {
            "nct_id": "NCT00036036", 
            "org_study_id": "OSI-461-003"
        }, 
        "intervention": {
            "intervention_name": "CP-461", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "renal", 
            "renal cell cancer", 
            "renal cell carcinoma", 
            "kidney cancer"
        ], 
        "lastchanged_date": "October 14, 2011", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90095"
                }, 
                "name": "UCLA Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of CP-461 in Patients With Advanced Renal Cell Cancer", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00036036"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "OSI Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2011"
    }, 
    "geocoordinates": {
        "UCLA Medical Center": "34.052 -118.244"
    }
}